Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Signs of thromboembolic events must be monitored in bevacizumab-treated cancer patients

04 Jan 2018

Thromboembolism is a major cause of death in patients with cancer, which is why clinicians should check for the symptoms of thromboembolic events right from the initial stages of bevacizumab treatment, suggests a recent study.

During the sample period, a total of 6,076 patients developed adverse events. Of these, 233 and 453 developed arterial and venous thromboembolic events, respectively.

Based on logistic analysis, the presence of cancer was found to be a significant predictor for both arterial and venous thromboembolic events. Other risk factors for arterial thromboembolic event included age (≥70 years) and histories of either hypertension or diabetes mellitus.

Median cumulative times of onset were 60 days for arterial thromboembolic event and 80 days for venous thromboembolic event, and were not significantly different by the log-rank test. The chi-square test suggested that the rate of unfavourable outcomes was higher after developing arterial thromboembolic event than after venous thromboembolic event.

The authors used adverse event data recorded in the Japanese Adverse Drug Event Report database between January 2004 and January 2015, and classified these into two groups by age and five groups by cancer type after screening the data using the generic drug name bevacizumab.

The authors also categorized the histories of disorders. Arterial and venous thromboembolic events were classified as “favourable” or “unfavourable” outcomes.

In one study, the combination of bevacizumab plus erythropoietin stimulating agent (ESA) was found to increase the incidence of thromboembolic events compared with either agent alone with chemotherapy. Median time of onset was significantly shorter in the combination group than in the bevacizumab group. Researchers suggested that prior venous thromboembolic event, cardiac disease, obesity, and exogenous hormone use should be considered when using the combination of bevacizumab and ESA. [Am J Clin Oncol 2010;33:36-42]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.